ArticleEuropean journal of pediatrics2026
PODiaCarD: a prototype of a digital twin platform for the management of pediatric obesity and related cardiometabolic complications.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial Intelligence for Weight Management in Children: A Narrative Review.Healthcare (Basel, Switzerland) · 2026Review
- The Potential of Digital Twins for Pediatric Rare Diseases.CPT: pharmacometrics & systems pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Childhood obesity is the main driver of early metabolic risk, predisposing to cardiovascular disease (CVD) and type 2 diabetes (T2D), which cause millions of deaths worldwide. Their progression is influenced by biological, behavioral, and environmental factors. Digital Twin Systems (DTS) offer innovative ways to monitor and predict cardiometabolic risk. This work presents a prototype digital twin platform called PODiaCarD designed for managing pediatric obesity and related cardiometabolic complications. The system integrates clinical, anthropometric, and lifestyle data with machine learning to estimate outcomes in youth. Built on a three-layer architecture (frontend, backend, predictive engine), PODiaCarD ensures scalability, observability, and reproducibility while enabling continuous model improvement. Models, trained on the PODiaCar project dataset (n = 552, 12.2 ± 2.9 years) with cross-validation and target-specific algorithms, predict eight key metabolic outcomes. The infrastructure follows privacy-by-design and GDPR standards, ensuring security, auditability, and clinical compliance. PODiaCarD achieved excellent performance for TyG index (F1 = 0.975 ± 0.014, random forest) and solid results for HbA1C (F1 = 0.844 ± 0.028, random forest). Moderate accuracy was observed for HOMA (F1 = 0.670 ± 0.070, Gradient Boosting). In contrast, models for blood pressure (R
conclusionsPODiaCarD is a promising tool for managing pediatric obesity and complications. It integrates clinical, anthropometric, and behavioral data with ML-based models to support pediatricians in early risk detection, dynamic monitoring, and personalized prevention. Its federated design allows continuous dataset growth and improved predictive performance, strengthening its role in pediatric cardiometabolic care. WHAT IS KNOWN: • Pediatric obesity is a major early driver of cardiometabolic risk; body mass index, waist circumference, and lipid profile are key indicators of insulin resistance, type 2 diabetes, and cardiovascular diseases. Existing pediatric predictive models are often static and limited in longitudinal integration. • Digital Twin Systems enable dynamic monitoring and "what-if" simulations in healthcare, but cardiometabolic applications in pediatric populations remain scarce and insufficiently validated. WHAT IS NEW: • PODiaCarD introduces a federated pediatric digital twin that integrates clinical, anthropometric, and lifestyle data with machine learning to dynamically update individual cardiometabolic risk profiles over time. • The platform achieves strong performance for insulin resistance surrogates and HbA1c prediction, provides explainable AI outputs, ensures privacy-by-design, and supports scalable, multi-centre personalized prevention strategies.
Indexed as
Identifiers
41533053What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.